EPO-906 (Novartis).
Novartis Pharma AG is developing EPO-906, an intravenous formulation microtubular depolymerization inhibitor (microtubule stabilizer), for the potential treatment of cancer.
Galmarini
Carlos María
CM
University Lyon, INSERM 590, 8 Avenue Rockefeller, 69373 Lyon, France. fgalma@rockefeller.univ-lyon1.fr
Dumontet
Charles
C
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D034261:Epothilones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D034261:Epothilones; C093788:epothilone B